Catherine R Lesko

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3217528/publications.pdf

Version: 2024-02-01

84 papers 1,711 citations

331670 21 h-index 36 g-index

85 all docs 85 docs citations

85 times ranked 2843 citing authors

#	Article	IF	CITATIONS
1	Generalizing Study Results. Epidemiology, 2017, 28, 553-561.	2.7	181
2	Transportability of Trial Results Using Inverse Odds of Sampling Weights. American Journal of Epidemiology, 2017, 186, 1010-1014.	3.4	181
3	Target Validity and the Hierarchy of Study Designs. American Journal of Epidemiology, 2019, 188, 438-443.	3.4	95
4	A Systematic Review and Meta-regression of Temporal Trends in Adult CD4+ Cell Count at Presentation to HIV Care, 1992-2011. Clinical Infectious Diseases, 2013, 57, 1027-1037.	5 . 8	68
5	HIV and COVID-19: Intersecting Epidemics With Many Unknowns. American Journal of Epidemiology, 2021, 190, 10-16.	3.4	62
6	The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009–11. International Journal of Epidemiology, 2016, 45, 140-150.	1.9	53
7	A longitudinal, HIV care continuum. Aids, 2016, 30, 2227-2234.	2.2	49
8	When to Censor?. American Journal of Epidemiology, 2018, 187, 623-632.	3.4	46
9	Collaborative, pooled and harmonized study designs for epidemiologic research: challenges and opportunities. International Journal of Epidemiology, 2018, 47, 654-668.	1.9	45
10	The Association Between Changes in Alcohol Use and Changes in Antiretroviral Therapy Adherence and Viral Suppression Among Women Living with HIV. AIDS and Behavior, 2017, 21, 1836-1845.	2.7	41
11	Effects of Antiretroviral Therapy and Depressive Symptoms on All-Cause Mortality Among HIV-Infected Women. American Journal of Epidemiology, 2017, 185, 869-878.	3.4	38
12	Bias Due to Confounders for the Exposure–Competing Risk Relationship. Epidemiology, 2017, 28, 20-27.	2.7	38
13	On the Need to Revitalize Descriptive Epidemiology. American Journal of Epidemiology, 2022, 191, 1174-1179.	3.4	38
14	Ten-year Survival by Race/Ethnicity and Sex Among Treated, HIV-infected Adults in the United States. Clinical Infectious Diseases, 2015, 60, 1700-1707.	5 . 8	33
15	Methodologic Issues when Estimating Risks in Pharmacoepidemiology. Current Epidemiology Reports, 2016, 3, 285-296.	2.4	31
16	Retention, Antiretroviral Therapy Use and Viral Suppression by History of Injection Drug Use Among HIV-Infected Patients in an Urban HIV Clinical Cohort. AIDS and Behavior, 2017, 21, 1016-1024.	2.7	30
17	Considerations when assessing heterogeneity of treatment effect in patient-centered outcomes research. Journal of Clinical Epidemiology, 2018, 100, 22-31.	5. O	27
18	An application of restricted mean survival time in a competing risks setting: comparing time to ART initiation by injection drug use. BMC Medical Research Methodology, 2018, 18, 27.	3.1	27

#	Article	IF	Citations
19	Mechanisms Underlying HIV-Associated Noninfectious Lung Disease. Chest, 2017, 152, 1053-1060.	0.8	24
20	Critical Review. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 489-494.	2.1	23
21	Immune Status and Associated Mortality After Cancer Treatment Among Individuals With HIV in the Antiretroviral Therapy Era. JAMA Oncology, 2020, 6, 227.	7.1	23
22	The HIV Care Cascade. Sexually Transmitted Diseases, 2014, 41, 41-42.	1.7	22
23	Do Symptoms of Depression Interact with Substance Use to Affect HIV Continuum of Care Outcomes?. AIDS and Behavior, 2019, 23, 580-591.	2.7	22
24	Measurement of Current Substance Use in a Cohort of HIV-Infected Persons in Continuity HIV Care, 2007–2015. American Journal of Epidemiology, 2018, 187, 1970-1979.	3.4	20
25	Biopsychosocial Mechanisms Linking Gender Minority Stress to HIV Comorbidities Among Black and Latina Transgender Women (LITE Plus): Protocol for a Mixed Methods Longitudinal Study. JMIR Research Protocols, 2020, 9, e17076.	1.0	20
26	Nonâ€Hispanic Black and Hispanic Patients Have Worse Outcomes Than White Patients Within Similar Stages of Peripheral Artery Disease. Journal of the American Heart Association, 2022, 11, e023396.	3.7	20
27	Marijuana use and HIV treatment outcomes among PWH receiving care at an urban HIV clinic. Journal of Substance Abuse Treatment, 2017, 82, 102-106.	2.8	18
28	Telemedicine and visit completion among people with HIV during the coronavirus disease 2019 pandemic compared with prepandemic. Aids, 2022, 36, 355-362.	2.2	18
29	Alcohol Use Patterns and Subsequent Sexual Behaviors Among Women, Men who have Sex with Men and Men who have Sex with Women Engaged in Routine HIV Care in the United States. AIDS and Behavior, 2019, 23, 1634-1646.	2.7	16
30	Recent Substance Use and Probability of Unsuppressed HIV Viral Load Among Persons on Antiretroviral Therapy in Continuity Care. American Journal of Epidemiology, 2019, 188, 1830-1837.	3.4	15
31	Target Validity: Bringing Treatment of External Validity in Line with Internal Validity. Current Epidemiology Reports, 2020, 7, 117-124.	2.4	15
32	Variation in estimated viral suppression associated with the definition of viral suppression used. Aids, 2020, 34, 1519-1526.	2.2	15
33	Generalizing randomized trial findings to a target population using complex survey population data. Statistics in Medicine, 2021, 40, 1101-1120.	1.6	15
34	Multiple Imputation to Account for Measurement Error in Marginal Structural Models. Epidemiology, 2015, 26, 645-652.	2.7	14
35	Outcomes of pharmacist-assisted management of antiretroviral therapy in patients with HIV infection: A risk-adjusted analysis. American Journal of Health-System Pharmacy, 2015, 72, 1463-1470.	1.0	13
36	Association of injection drug use with incidence of HIV-associated non-AIDS-related morbidity by age, 1995–2014. Aids, 2016, 30, 1447-1455.	2.2	13

#	Article	IF	CITATIONS
37	One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States. Clinical Infectious Diseases, 2019, 68, 795-802.	5.8	13
38	Limitations of the UNAIDS 90-90-90 metrics: a simulation-based comparison of cross-sectional and longitudinal metrics for the HIV care continuum. Aids, 2020, 34, 1047-1055.	2.2	13
39	A randomized trial of levonorgestrel intrauterine system insertion 6 to 48 h compared to 6 weeks after vaginal delivery; lessons learned. Contraception, 2015, 91, 284-288.	1.5	12
40	An Illustration of Inverse Probability Weighting to Estimate Policy-Relevant Causal Effects. American Journal of Epidemiology, 2016, 184, 336-344.	3.4	12
41	Decreased Alcohol Consumption in an Implementation Study of Computerized Brief Intervention among HIV Patients in Clinical Care. AIDS and Behavior, 2021, 25, 4074-4084.	2.7	12
42	Depression and HIV viral nonsuppression among people engaged in HIV care in an urban clinic, 2014–2019. Aids, 2021, 35, 2017-2024.	2.2	12
43	The Effect of Buprenorphine on Human Immunodeficiency Virus Viral Suppression. Clinical Infectious Diseases, 2021, 73, 1951-1956.	5.8	12
44	Differential effects of perceived stress on alcohol consumption in moderate versus heavy drinking HIV-infected women. Drug and Alcohol Dependence, 2017, 178, 380-385.	3.2	11
45	Associations of Drug Use, Violence, and Depressive Symptoms with Sexual Risk Behaviors Among Women with Alcohol Misuse. Women's Health Issues, 2018, 28, 367-374.	2.0	11
46	Causal Inference in the Face of Competing Events. Current Epidemiology Reports, 2020, 7, 125-131.	2.4	11
47	Changing Patterns of Alcohol Use and Probability of Unsuppressed Viral Load Among Treated Patients with HIV Engaged in Routine Care in the United States. AIDS and Behavior, 2021, 25, 1072-1082.	2.7	11
48	Persistence on oral pre-exposure prophylaxis (PrEP) among female sex workers in eThekwini, South Africa, 2016–2020. PLoS ONE, 2022, 17, e0265434.	2.5	11
49	Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: an application of the parametric g-formula. Annals of Epidemiology, 2017, 27, 783-789.e2.	1.9	10
50	Time Spent with HIV Viral Load > 1500 Copies/mL Among Persons Engaged in Continuity HIV Care in an Urban Clinic in the United States, 2010–2015. AIDS and Behavior, 2018, 22, 3443-3450.	2.7	10
51	Missingness in the Setting of Competing Risks: from Missing Values to Missing Potential Outcomes. Current Epidemiology Reports, 2018, 5, 153-159.	2.4	10
52	Informative censoring by health plan disenrollment among commercially insured adults. Pharmacoepidemiology and Drug Safety, 2019, 28, 640-648.	1.9	10
53	Association of History of Injection Drug Use with External Cause-Related Mortality Among Persons Linked to HIV Care in an Urban Clinic, 2001–2015. AIDS and Behavior, 2019, 23, 3286-3293.	2.7	10
54	From Epidemiologic Knowledge to Improved Health: A Vision for Translational Epidemiology. American Journal of Epidemiology, 2019, 188, 2049-2060.	3.4	10

#	Article	IF	CITATIONS
55	The Epidemiologic Toolbox: Identifying, Honing, and Using the Right Tools for the Job. American Journal of Epidemiology, 2020, 189, 511-517.	3.4	10
56	Tobacco Smoking, Substance Use, and Mental Health Symptoms in People with HIV in an Urban HIV Clinic. Journal of Health Care for the Poor and Underserved, 2019, 30, 1083-1102.	0.8	9
57	COVID-19 and the HIV continuum in people living with HIV enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts. Drug and Alcohol Dependence, 2022, 241, 109355.	3.2	9
58	Censoring for Loss to Follow-up in Time-to-event Analyses of Composite Outcomes or in the Presence of Competing Risks. Epidemiology, 2019, 30, 817-824.	2.7	8
59	Gone But Not Lost. Epidemiology, 2020, 31, 570-577.	2.7	8
60	Cardiovascular disease risk among transgender women living with HIV in the United States. PLoS ONE, 2020, 15, e0236177.	2.5	7
61	Teaching Epidemiology Online (Pandemic Edition). American Journal of Epidemiology, 2021, 190, 1183-1189.	3.4	7
62	Invited Commentary: Causal Inference Across Space and Timeâ€"Quixotic Quest, Worthy Goal, or Both?. American Journal of Epidemiology, 2017, 186, 143-145.	3.4	6
63	Alcohol Use Disorder and Recent Alcohol Use and HIV Viral Non-Suppression Among People Engaged in HIV Care in an Urban Clinic, 2014–2018. AIDS and Behavior, 2022, 26, 1299-1307.	2.7	4
64	The relationship of alcohol and other drug use during the COVID-19 pandemic among people with or at risk of HIV; A cross-sectional survey of people enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts. Drug and Alcohol Dependence, 2022, 241, 109382.	3.2	4
65	The Authors Respond. Epidemiology, 2018, 29, e14-e15.	2.7	3
66	Ancillary service needs among persons new to HIV care and the relationship between needs and late presentation to care. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 1131-1139.	1.2	3
67	What Happens to Your Manuscript: Characteristics of Papers Published in Volume 188. American Journal of Epidemiology, 2020, 189, 627-630.	3.4	3
68	Reducing the Population Burden of Coronary Heart Disease by Modifying Adiposity: Estimates From the ARIC Study. Journal of the American Heart Association, 2020, 9, e012214.	3.7	3
69	Computer delivered intervention for alcohol and sexual risk reduction among women attending an urban sexually transmitted infection clinic: A randomized controlled trial. Addictive Behaviors Reports, 2021, 14, 100367.	1.9	3
70	Estimating multiple timeâ€fixed treatment effects using a semiâ€Bayes semiparametric marginal structural Cox proportional hazards regression model. Biometrical Journal, 2018, 60, 100-114.	1.0	2
71	Short Communication: Differences in 5-Year Survival After Cancer Diagnosis Between HIV Clinic Enrollees and the General U.S. Population. AIDS Research and Human Retroviruses, 2020, 36, 116-118.	1.1	2
72	Combining Effect Estimates Across Cohorts and Sufficient Adjustment Sets for Collaborative Research. Epidemiology, 2021, 32, 421-424.	2.7	2

#	Article	IF	CITATIONS
73	Exploring definitions of retention in care for people living with HIV in the United States in the modern treatment era. Aids, 2022, 36, 1181-1189.	2.2	2
74	The Best of Both Worlds. Sexually Transmitted Diseases, 2016, 43, 41-43.	1.7	1
75	Influence of Injection Drug Use–Related HIV Acquisition on CD4 Response to First Antiretroviral Therapy Regimen Among Virally Suppressed Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 317-324.	2.1	1
76	The Promise, and Challenges, of Methods to Enhance the External Validity of Randomized Trial Results. Clinical Pharmacology and Therapeutics, 2020, 108, 1132-1134.	4.7	1
77	A comparison of cancer stage at diagnosis and treatment initiation between enrollees in an urban HIV clinic and SEER. Cancer Causes and Control, 2020, 31, 511-516.	1.8	1
78	Editorial: Robust Sensitivities. American Journal of Epidemiology, 2021, 190, 1437-1448.	3.4	1
79	48. Time Between Viral Loads for Suppressed and Non-Suppressed People with HIV During the COVID-19 Pandemic Compared to Pre-Pandemic. Open Forum Infectious Diseases, 2021, 8, S34-S35.	0.9	1
80	Generalizability and scalability of HIV â€~treatment as prevention'. Aids, 2013, 27, 2493-2494.	2.2	0
81	Death after diagnosis of noncommunicable disease comorbid conditions, stratified by injection drug use. Aids, 2019, 33, 285-293.	2.2	0
82	A learning algorithm for predicting mental health symptoms and substance use. Journal of Psychiatric Research, 2021, 134, 22-29.	3.1	0
83	What Happens to Your Manuscript: Characteristics of Papers Published in Volume 189. American Journal of Epidemiology, 2021, 190, 1705-1709.	3.4	0
84	The temporal relationship of alcohol use and subsequent self-reported health status among people with HIV., 2023, 9, 100020.		0